NCT06143007View on ClinicalTrials.gov

A Phase 1 Study of BB3008 in Participants With Advanced Solid Tumors

PHASE1RecruitingINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

October 26, 2023

Primary Completion Date

November 30, 2025

Study Completion Date

April 30, 2026

Conditions
Advanced Solid Tumor
Interventions
DRUG

BB3008 tablet

BB3008 tablets will be administered orally once daily (QD).

Trial Locations (2)

100005

NOT_YET_RECRUITING

Peking Union Medical College Hospital, Beijing

100021

RECRUITING

Cancer Hospital Chinese Academy of Medical Sciences, Beijing

All Listed Sponsors
lead

BrodenBio Co., Ltd.

INDUSTRY